Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
3-F-BPAP
3-F-BPAP is a trifluorinated derivative of benzofuranylpropylaminopentane (BPAP) and is an antagonist of the monoaminergic activity enhancer (MAE) effects of the tryptamine-related BPAP.
Conversely, 3-F-BPAP does not antagonize the catecholaminergic activity enhancer (CAE) effects of the phenethylamine-derived selegiline (L-deprenyl) and phenylpropylaminopentane (PPAP). This suggests that different MAEs like BPAP and selegiline may not be identical in their actions and might be acting via different receptor subtypes. In contrast to 3-F-BPAP however, the TAAR1 antagonist EPPTB antagonizes the MAE effects of both BPAP and selegiline.
3-F-BPAP has a weak MAE effect itself but with much lower potency than BPAP. The effects of MAEs like BPAP and selegiline appear to be mediated by TAAR1 agonism, and hence 3-F-BPAP may be acting as a TAAR1 antagonist (or weak partial agonist).
3-F-BPAP was developed by József Knoll and colleagues and was first described in the scientific literature in 2002.
Hub AI
3-F-BPAP AI simulator
(@3-F-BPAP_simulator)
3-F-BPAP
3-F-BPAP is a trifluorinated derivative of benzofuranylpropylaminopentane (BPAP) and is an antagonist of the monoaminergic activity enhancer (MAE) effects of the tryptamine-related BPAP.
Conversely, 3-F-BPAP does not antagonize the catecholaminergic activity enhancer (CAE) effects of the phenethylamine-derived selegiline (L-deprenyl) and phenylpropylaminopentane (PPAP). This suggests that different MAEs like BPAP and selegiline may not be identical in their actions and might be acting via different receptor subtypes. In contrast to 3-F-BPAP however, the TAAR1 antagonist EPPTB antagonizes the MAE effects of both BPAP and selegiline.
3-F-BPAP has a weak MAE effect itself but with much lower potency than BPAP. The effects of MAEs like BPAP and selegiline appear to be mediated by TAAR1 agonism, and hence 3-F-BPAP may be acting as a TAAR1 antagonist (or weak partial agonist).
3-F-BPAP was developed by József Knoll and colleagues and was first described in the scientific literature in 2002.